Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein

Bin Zhao(University of California San Diego), Li Li(University of Michigan), Q. Richard Lu(University of California San Diego), Lloyd H. Wang(University of California San Diego), Chen‐Ying Liu(Fudan University), Qun‐Ying Lei(Fudan University), Kun‐Liang Guan(University of California San Diego)
Genes & Development
January 1, 2011
Cited by 665Open Access
Full Text

Abstract

The Yes-associated protein (YAP) is a transcription coactivator that plays a crucial role in organ size control by promoting cell proliferation and inhibiting apoptosis. The Hippo tumor suppressor pathway inhibits YAP through phosphorylation-induced cytoplasmic retention and degradation. Here we report a novel mechanism of YAP regulation by angiomotin (AMOT) family proteins via a direct interaction. Knockdown of AMOT family protein AMOTL2 in polarized Madin-Darby canine kidney (MDCK) cells leads to YAP activation, as indicated by decreased YAP tight junction localization, attenuated YAP phosphorylation, accumulation of nuclear YAP, and induction of YAP target gene expression. Transcriptional coactivator with PDZ-binding motif (TAZ), the YAP paralog, is also regulated by AMOT in a similar fashion. Furthermore, AMOTL2 knockdown results in loss of cell contact inhibition in a manner dependent on the functions of YAP and TAZ. Our results indicate a potential tumor-suppressing role of AMOT family proteins as components of the Hippo pathway, and demonstrate a novel mechanism of YAP and TAZ inhibition by AMOT-mediated tight junction localization. These observations provide a potential link between the Hippo pathway and cell contact inhibition.


Related Papers

No related papers found

Powered by citation graph analysis